Cyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice
Andrology · 2026-09 · 14 (6) · 1472-1478
DOI: 10.1111/andr.70227 ↗At a glance
Journal article in Andrology, published online on 2026-03-29. Written by Jisun Paik and 3 co-authors. Institution: Department of Comparative Medicine, University of Washington, Seattle, Washington, USA. Major MEDLINE topics: Spermatogenesis, Contraceptive Agents, Male, Naphthalenes. Cited 2 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIDDK NIH HHS, from NIDDK, from NICHD.
Abstract (original language)
Background
Retinoic acid plays a critical role in spermatogenesis during both spermatogonial differentiation and spermiation. Mice lacking enzymes that synthesize retinoic acid, Aldh1a1/1a2 , in the testes are infertile. WIN 18,446 reversibly inhibits spermatogenesis by inhibiting ALDH1A1/1A2 and is a promising approach to male contraception. Previously, we demonstrated the kinetics, efficacy, and reversibility of continuous treatment with WIN18,446 as a male contraceptive.
Objective
We sought to investigate whether cyclic administration of WIN 18,446 could be as effective at inhibiting spermatogenesis as continuous treatment with WIN 18,446 while reducing the risk of potential testicular damage from continuous treatment. We studied testicular histology and sperm counts in response to continuous vs. cyclic treatment of WIN 18,446 and assessed recovery from the two treatment regimens. Materials and Methods Male mice were fed a diet containing WIN 18,446 for 15 weeks, followed by a diet without the drug for up to 16 weeks. For cyclic treatment, male mice were fed the WIN 18,446‐containing diet for 4 weeks, followed by three cycles of 2‐weeks of control diet, followed by 2‐weeks of WIN 18,446 diet for 12 additional weeks. After the last cyclic treatment, drug treatment was discontinued, and animals were allowed to recover for 8 weeks. Mice were euthanized at predetermined time points to assess recovery of spermatogenesis by testicular histology and sperm counts.
Results
Testis weights and sperm counts were similar between cyclically treated mice and mice treated with WIN 18,446 continuously for 15 weeks. Testes of mice under cyclic treatment contained spermatocytes/spermatids, but not mature, normal spermatozoa, while those from the mice under continuous treatment had only spermatogonia. Importantly, spermatogenesis recovered more quickly when mice were treated cyclically compared to those receiving continuous treatment based on testes weight and histology.
Conclusions
Cyclic treatment of mice with the ALDH1A inhibitor WIN 18,446 is as efficacious as continuous treatment in suppressing spermatogenesis and may allow for faster recovery of spermatogenesis after the cessation of drug treatment, and reduce the chance of injury to the testes from continuous treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Comparative Medicine, University of Washington, Seattle, Washington, USA.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID profiles: John K Amory
Funding
- NIDDK NIH HHS
- from NIDDK
- from NICHD
Cite
APA
Paik, J., Snyder, J. M., Martin, H. A., & Amory, J. K. (2026). Cyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice. Andrology, 14(6), 1472-1478. https://doi.org/10.1111/andr.70227
Vancouver
Paik J, Snyder JM, Martin HA, Amory JK. Cyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice. Andrology. 2026;14(6):1472-1478. doi:10.1111/andr.70227
BibTeX
@article{Paik2026,
author = {Paik, Jisun and Snyder, Jessica M and Martin, Haley A and Amory, John K},
title = {Cyclic Treatment With WIN 18,446, a Potential Male Contraceptive, is as Effective as Continuous Treatment for Suppression of Spermatogenesis in Mice},
journal = {Andrology},
year = {2026},
volume = {14},
number = {6},
pages = {1472--1478},
doi = {10.1111/andr.70227}
}
EUVIMED